Jennifer J Chang1,2, Neaka Mohtashemi1, Debika Bhattacharya3. 1. UCLA CARE Center, Division of Infectious Diseases, David Geffen School of Medicine, University of California, Los Angeles, 10833 Le Conte Avenue, 37-121 CHS, Los Angeles, CA, 90095, USA. 2. Department of Infectious Diseases, Kaiser Permanente at Los Angeles Medical Center, 1505 N. Edgemont St., 2nd Floor, Los Angeles, CA, 90027, USA. 3. UCLA CARE Center, Division of Infectious Diseases, David Geffen School of Medicine, University of California, Los Angeles, 10833 Le Conte Avenue, 37-121 CHS, Los Angeles, CA, 90095, USA. debikab@mednet.ucla.edu.
Abstract
PURPOSE OF REVIEW: The purpose of this review is to summarize the prevalence and clinical implications of the isolated anti-HBc serologic profile in HIV-infected individuals. We highlight the rare but important issue of HBV reactivation in the setting of HCV therapy and describe an approach to management. RECENT FINDINGS: The isolated anti-HBc pattern, a profile that most often indicates past exposure to HBV with waning anti-HBs immunity, is found commonly in HIV-infected individuals, particularly those with HCV. Some large cohort studies demonstrate an association with advanced liver disease, while others do not. Conversely, meta-analyses have found an association between occult HBV infection (a component of the isolated anti-HBc pattern) and advanced liver disease and hepatocellular carcinoma in HIV-uninfected individuals. In HIV-uninfected individuals with anti-HBc positivity, HBV reactivation has been reported in patients receiving HCV therapy. This phenomenon is likely the result of disinhibition of HBV with HCV eradication. In HIV-infected patients, the long-term liver outcomes associated with the isolated anti-HBc pattern remain to be fully elucidated, supporting the need for large cohort studies with longitudinal follow-up. HBV reactivation during HCV DAA therapy has been well-described in HIV-uninfected cohorts and can inform algorithms for the screening and management of the isolated anti-HBc pattern in this population.
PURPOSE OF REVIEW: The purpose of this review is to summarize the prevalence and clinical implications of the isolated anti-HBc serologic profile in HIV-infected individuals. We highlight the rare but important issue of HBV reactivation in the setting of HCV therapy and describe an approach to management. RECENT FINDINGS: The isolated anti-HBc pattern, a profile that most often indicates past exposure to HBV with waning anti-HBs immunity, is found commonly in HIV-infected individuals, particularly those with HCV. Some large cohort studies demonstrate an association with advanced liver disease, while others do not. Conversely, meta-analyses have found an association between occult HBV infection (a component of the isolated anti-HBc pattern) and advanced liver disease and hepatocellular carcinoma in HIV-uninfected individuals. In HIV-uninfected individuals with anti-HBc positivity, HBV reactivation has been reported in patients receiving HCV therapy. This phenomenon is likely the result of disinhibition of HBV with HCV eradication. In HIV-infectedpatients, the long-term liver outcomes associated with the isolated anti-HBc pattern remain to be fully elucidated, supporting the need for large cohort studies with longitudinal follow-up. HBV reactivation during HCVDAA therapy has been well-described in HIV-uninfected cohorts and can inform algorithms for the screening and management of the isolated anti-HBc pattern in this population.
Authors: Jeffrey M Collins; Kara Loren Raphael; Charles Terry; Emily J Cartwright; Anjana Pillai; Frank A Anania; Monica M Farley Journal: Clin Infect Dis Date: 2015-06-16 Impact factor: 9.079
Authors: R Palacios; R Mata; A Hidalgo; L Muñoz; I Viciana; A Del Arco; L F López-Cortés; A Peña; J de la Torre; J Santos Journal: HIV Clin Trials Date: 2008 Sep-Oct
Authors: Azwidowi Lukhwareni; Rosemary J Burnett; S Gloria Selabe; M Olga Mzileni; M Jeffrey Mphahlele Journal: J Med Virol Date: 2009-03 Impact factor: 2.327
Authors: Hussein Mukasa Kafeero; Dorothy Ndagire; Ponsiano Ocama; Charles Drago Kato; Eddie Wampande; Abdul Walusansa; Henry Kajumbula; David Kateete; Hakim Sendagire Journal: Sci Rep Date: 2022-05-06 Impact factor: 4.996
Authors: Caroline Schmidbauer; David Chromy; Victor U Schmidbauer; Michael Schwarz; Mathias Jachs; David J M Bauer; Teresa Binter; Michael Apata; Dung T Nguyen; Mattias Mandorfer; Benedikt Simbrunner; Armin Rieger; Florian Mayer; Monika Breuer; Robert Strassl; Ralf Schmidt; Heidemarie Holzmann; Michael Trauner; Michael Gschwantler; Thomas Reiberger Journal: Liver Int Date: 2021-08-05 Impact factor: 8.754